SAN DIEGO , April 29, 2016 /PRNewswire/ -- Biocept, Inc. (" Biocept ") (Nasdaq: BIOC) today announced that it has priced a registered public offering of an aggregate of approximately 5.0 million shares of common stock at a price to the public of $1.00 per share.
SAN DIEGO , April 28, 2016 /PRNewswire/ -- Biocept, Inc. (" Biocept ") (Nasdaq: BIOC) today announced a proposed registered public offering of its common stock and warrants, subject to market and other conditions. The offering is subject to market and other conditions, and there can be no assurance
Study focuses on Resistance Mechanisms in Non-Small Cell Lung Cancer; Data Expected to Further Support the Clinical Utility of Biocept's Liquid Biopsy Technology
SAN DIEGO , April 6, 2016 /PRNewswire/ -- Biocept, Inc. ( NASDAQ : BIOC), a leading molecular diagnostics company that commercializes and develops liquid biopsy tests for cancer profiling and monitoring, announces that President and CEO Michael W. Nall is scheduled to present a corporate overview
SAN DIEGO , March 23, 2016 /PRNewswire/ -- Biocept, Inc. ( NASDAQ : BIOC), a molecular diagnostics company commercializing and developing blood-based biomarkers to improve the detection and treatment of cancer, announces that Interim Chief Financial Officer Mark Foletta has received the CFO
Trial Data Expected to Provide Further Clinical Validation of Biocept's CTC and ctDNA Liquid Biopsy Testing and Platforms for Biomarker Detection in Patients Diagnosed with Non-Small Cell Lung Cancer
SAN DIEGO , March 10, 2016 /PRNewswire/ -- Biocept, Inc. ( NASDAQ : BIOC), a molecular diagnostics company commercializing and developing liquid biopsies to improve the detection and treatment of cancer, announces that Progenetics LTD will market and distribute Biocept's complete portfolio of
Billable sample volume increases by more than 30% for third consecutive quarter reaching full-year 2015 total of 1,8242015 revenues grow more than three-foldConference call begins at 4:30 p.m. Eastern time today
